Why Moderna may have an edge in the vaccine race: refrigeration
The biotech firm claims its candidate can protect against the lethal disease and can be stored in a normal refrigerator for 30 days.
It’s still early days, but the news from the COVID-19 vaccine front continues to bring much-needed hope to a virus-ravaged world.
On Monday, Moderna Therapeutics announced the first batch of interim results from its highly watched phase three clinical trial. The company claims its vaccine candidate is 94.5-percent effective—a startling sequel to last week’s revelation by the pharmaceutical companies Pfizer and BioNTech that their version had a similar success rate. On November 18, Pfizer doubled down on its claim and concluded its trial, with the company ultimately seeking FDA approval for its candidate by week’s end.
Given both are mRNA vaccines, the news provides additional proof that this cutting-edge technology might be ready for the first
